GO:0004459 L-lactate dehydrogenase (NAD+) activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004459 describes the NAD+-dependent interconversion of (S)-lactate and pyruvate, a central redox reaction in glycolysis, fermentation, and cellular metabolism.
• The reaction is reversible and follows the formal equation (S)-lactate + NAD+ = pyruvate + NADH + H+, as defined by QuickGO and supported by enzymological studies.
• L-lactate dehydrogenase (LDH) enzymes are widely distributed, from strictly anaerobic bacteria to humans, and often function as homotetramers with allosteric regulation.
• LDH activity is a common clinical biomarker; total LDH activity in serum is measured to assess tissue damage, hemolysis, and tumor burden.
• Pharmacological inhibition of LDH, for example by galloflavin, can suppress MYC-driven lymphoma cell growth through NAD/NADH-dependent mechanisms.
• Studying GO:0004459 benefits from CRISPR knockout, point-mutation, knock-in, and overexpression models to dissect isoform-specific and catalytic functions.
Description
L-lactate dehydrogenase (NAD+) activity, classified under GO:0004459, is a fundamental molecular function that catalyzes the reversible oxidation of (S)-lactate to pyruvate with the concomitant reduction of NAD+ to NADH. This reaction sits at the crossroads of anaerobic glycolysis and oxidative metabolism, allowing cells to regenerate NAD+ and sustain ATP production when oxygen is limited. The enzyme is conserved across all domains of life, from strictly anaerobic bacteria that rely on soluble NAD+-dependent L-lactate dehydrogenases for fermentation to humans, where LDH isoenzymes are used clinically as markers of tissue injury and tumor burden. Researchers study GO:0004459 because it directly impacts redox balance, metabolic flux, and the Warburg effect in cancer, and because its kinetic and allosteric properties are increasingly recognized as drug targets. Understanding the precise catalytic mechanism, regulation, and disease associations of L-lactate dehydrogenase (NAD+) activity is therefore essential for both basic metabolism research and translational applications.
L-lactate dehydrogenase (NAD+) activity At A Glance
| GO ID | GO:0004459 |
|---|---|
| GO term | L-lactate dehydrogenase (NAD+) activity |
| Ontology | molecular_function |
| Synonym | L-lactate dehydrogenase activity; L-lactic acid dehydrogenase activity; L-lactic dehydrogenase activity |
| Major function | Catalyzes the reversible conversion of (S)-lactate to pyruvate with NAD+ as electron acceptor |
| Reaction direction | Reversible; (S)-lactate + NAD+ = pyruvate + NADH + H+ |
| Cofactor | NAD+ (nicotinamide adenine dinucleotide, oxidized form) |
| Subcellular context | Cytoplasm and, for some isoforms, mitochondria; also found in anaerobic bacteria |
| Representative enzymes | LDHA, LDHB, LDHC, and bacterial L-lactate dehydrogenases |
What Is GO:0004459?
GO:0004459, L-lactate dehydrogenase (NAD+) activity, is defined by the Gene Ontology as the catalysis of the reaction: (S)-lactate + NAD+ = pyruvate + NADH + H+. In other words, it is the enzyme activity that transfers a hydride from L-lactate to the cofactor NAD+, producing pyruvate and the reduced cofactor NADH. This activity is synonymous with L-lactate dehydrogenase activity, L-lactic acid dehydrogenase activity, and L-lactic dehydrogenase activity. It is a molecular function term, meaning it describes what a protein does at the biochemical level rather than a biological process or cellular component.
Why Is L-lactate dehydrogenase (NAD+) activity Important in Cell Biology?
L-lactate dehydrogenase (NAD+) activity is essential for maintaining redox homeostasis and metabolic flexibility. By converting lactate to pyruvate and generating NADH, it links glycolysis, gluconeogenesis, and the tricarboxylic acid cycle, and it enables cells to survive hypoxic or anaerobic conditions. In clinical settings, total LDH activity is a long-standing biomarker for tissue damage, hemolysis, and cancer, and its inhibition is being explored as an anticancer strategy. Moreover, the enzyme is a model system for studying allosteric regulation, cofactor specificity, and protein evolution, as shown by structural and kinetic studies on bacterial and human enzymes. Consequently, GO:0004459 is relevant to cancer metabolism, neurodegeneration, infectious disease, and metabolic engineering.
• Maintains NAD+ regeneration during anaerobic glycolysis, supporting ATP production when oxidative phosphorylation is limited.
• Serves as a clinical biomarker: elevated serum LDH indicates cell turnover, tissue damage, or tumor burden.
• Contributes to the Warburg effect in cancer, where lactate production and LDH activity are often upregulated.
• Is a target for small-molecule inhibitors such as galloflavin, which suppresses lymphoma cell growth via NAD/NADH-dependent sirtuin-1 inhibition.
• Plays a role in the redox switch/redox coupling hypothesis, linking lactate and pyruvate to cellular signaling and metabolic compartmentation.
• Provides a model for allosteric regulation beyond simple effector-mediated tetramerization, as shown for L-lactate dehydrogenases.
• Is found in strictly anaerobic microorganisms, where soluble NAD+-dependent L-lactate dehydrogenases are key to fermentation.
• Thermophilic LDHs, such as that from Moorella thermoacetica, are studied for biotechnological applications and enzyme stability.
• Kinetic properties and inhibition by metabolites like oxaloacetate reveal regulatory nodes in central metabolism.
• Polymeric NAD derivatives can inhibit LDH activity, offering tools for probing cofactor binding and enzyme regulation.
What Happens During L-lactate dehydrogenase (NAD+) activity?
Substrate binding and cofactor recruitment
In simple terms: The enzyme grabs lactate and NAD+ to start the reaction.
The catalytic cycle begins with the binding of (S)-lactate and the oxidized cofactor NAD+ to the enzyme active site. Kinetic studies on bacterial L-lactate dehydrogenases, such as that from Alcaligenes eutrophus, have defined the ordered or random binding mechanisms and the role of NAD+ in orienting the substrate for hydride transfer. The enzyme typically functions as a homotetramer, and cofactor binding can influence subunit interactions and overall stability.
Hydride transfer and catalytic conversion
In simple terms: A hydride ion is moved from lactate to NAD+, turning lactate into pyruvate.
Once bound, the enzyme catalyzes the stereospecific transfer of a hydride from the C2 position of (S)-lactate to the nicotinamide ring of NAD+, yielding pyruvate and NADH. This step is reversible, and the equilibrium favors lactate formation under standard conditions, but the direction in vivo depends on substrate concentrations and redox state. The reaction also releases a proton (H+), consistent with the GO definition: (S)-lactate + NAD+ = pyruvate + NADH + H+.
Product release and enzyme turnover
In simple terms: The enzyme lets go of pyruvate and NADH so it can work again.
After catalysis, pyruvate and NADH are released from the active site, allowing the enzyme to enter another round of catalysis. Product release can be rate-limiting, and the kinetic properties of LDHs from different organisms vary widely, as shown for the thermophilic enzyme from Moorella thermoacetica and the strictly anaerobic bacterial enzymes. Inhibition by substrate analogs or polymeric NAD derivatives can block turnover, providing insights into regulatory mechanisms.
Allosteric regulation and tetramer dynamics
In simple terms: The enzyme can change shape and activity when other molecules bind to it.
Recent work has revealed that L-lactate dehydrogenases are subject to allosteric regulation that goes beyond simple effector-mediated tetramerization. For example, Cai et al. (2025) described allosteric mechanisms that modulate LDH activity through conformational changes and subunit communication. Such regulation allows the enzyme to respond to metabolic cues, such as changes in NAD+/NADH ratio or the presence of specific metabolites, thereby fine-tuning flux through lactate-producing and lactate-consuming pathways.
Key Genes Involved in GO:0004459 L-lactate dehydrogenase (NAD+) activity
The following genes encode proteins with L-lactate dehydrogenase (NAD+) activity or directly regulate this activity across species.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LDHA | Human L-lactate dehydrogenase A; converts pyruvate to lactate in anaerobic glycolysis | Target in cancer metabolism; knockout and inhibitors reduce tumor growth |
| LDHB | Human L-lactate dehydrogenase B; favors lactate oxidation to pyruvate | Isoform-specific functions in oxidative tissues; studied via knock-in and point mutants |
| LDHC | Testis-specific L-lactate dehydrogenase C | Role in sperm metabolism and fertility; potential contraceptive target |
| ldhA (bacterial) | Bacterial NAD+-dependent L-lactate dehydrogenase | Model for anaerobic fermentation and enzyme evolution |
| ldh (Moorella thermoacetica) | Thermophilic NAD+-dependent L-lactate dehydrogenase | Biotechnological applications and thermostability studies |
| ldh (Alcaligenes eutrophus) | Strict aerobe L-lactate dehydrogenase | Kinetic and inhibition studies with oxaloacetate |
| SIRT1 | NAD+-dependent deacetylase; modulated by LDH activity via NAD/NADH ratio | Link between LDH inhibition and MYC downregulation in lymphoma |
| MYC | Oncogene; downregulated upon LDH inhibition in Burkitt lymphoma | Readout for LDH-targeted therapy |
| HIF1A | Hypoxia-inducible factor; regulates LDHA expression | Context for hypoxic induction of LDH activity |
| PDHA1 | Pyruvate dehydrogenase; competes with LDH for pyruvate | Metabolic flux control between oxidation and fermentation |
| MPC1/MPC2 | Mitochondrial pyruvate carrier; affects pyruvate availability for LDH | Compartmentalization of lactate/pyruvate metabolism |
| MCT1 (SLC16A1) | Monocarboxylate transporter; exports lactate | Couples LDH activity to lactate shuttling |
| MCT4 (SLC16A3) | Monocarboxylate transporter; high-capacity lactate exporter | Hypoxic cancer cell metabolism |
| GAPDH | Glycolytic enzyme upstream of LDH; generates NADH | Redox balance and glycolytic flux |
| PKM | Pyruvate kinase; produces pyruvate for LDH | Metabolic context of LDH activity |
| NAMPT | NAD+ salvage enzyme; affects NAD+ availability for LDH | Regulation of NAD+-dependent enzymes |
| SLC25A11 | Mitochondrial oxoglutarate carrier; impacts NADH shuttling | Indirect regulation of LDH flux |
How Is L-lactate dehydrogenase (NAD+) activity Regulated?
L-lactate dehydrogenase (NAD+) activity is regulated at multiple levels. Transcriptionally, LDHA is induced by hypoxia-inducible factors (HIFs) under low oxygen, increasing lactate production. Post-translationally, the enzyme can be modified by phosphorylation and acetylation, although specific sites vary by isoform. Allosteric regulation by metabolites and cofactors modulates activity; for example, the NAD+/NADH ratio directly influences reaction direction, and recent studies have uncovered allosteric mechanisms beyond simple effector-mediated tetramerization. Additionally, inhibition by oxaloacetate and polymeric NAD derivatives has been documented, providing feedback control. The redox switch/redox coupling hypothesis posits that lactate and pyruvate exchange between cells and compartments acts as a signaling mechanism, further integrating LDH activity with cellular redox state.
L-lactate dehydrogenase (NAD+) activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LDHA | Cancer metabolism, lymphoma, hypoxia adaptation | LDHA knockout in cancer cell lines; xenograft models |
| LDHB | Oxidative metabolism, potential tumor suppressor context | LDHB overexpression or knock-in in cancer cells |
| SIRT1 | Lymphoma, NAD+-dependent signaling | SIRT1 knockout or point mutant to test galloflavin response |
| MYC | Burkitt lymphoma, oncogene addiction | MYC-driven lymphoma cells treated with LDH inhibitors |
| HIF1A | Hypoxia-related diseases, cancer | HIF1A knockout under hypoxia to assess LDHA induction |
Cancer metabolism and LDH inhibition
Many cancer cells rely on aerobic glycolysis and high LDH activity to sustain proliferation and survive hypoxic conditions. Galloflavin, a small-molecule LDH inhibitor, suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells through NAD/NADH-dependent inhibition of sirtuin-1. This illustrates how targeting GO:0004459 can disrupt oncogenic signaling and metabolic reprogramming. Elevated serum LDH is also a prognostic marker in lymphomas and other malignancies.
Ischemia, tissue damage, and hemolysis
Because LDH is abundant in many tissues, its release into serum indicates cell damage. Measurement of total LDH activity is a standard clinical assay for hemolysis, myocardial infarction, and other tissue injuries. The enzyme's role in anaerobic glycolysis makes it particularly relevant in ischemic conditions, where lactate accumulates and LDH helps regenerate NAD+ for continued ATP production.
Neurological and metabolic disorders
The redox switch/redox coupling hypothesis links lactate and pyruvate exchange to neuronal metabolism and signaling. Dysregulation of LDH activity may contribute to metabolic stress in the brain, although specific disease mechanisms require further study. Inborn errors affecting lactate metabolism can present with lactic acidosis, and LDH activity is part of the diagnostic workup.
From L-lactate dehydrogenase (NAD+) activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of LDHA reduce tumor growth? | LDHA knockout cell lines and mouse xenografts |
| How does a specific active-site residue affect catalysis? | Point mutation of catalytic residues in LDHA or LDHB, followed by kinetic assays |
| Can a disease-associated mutation alter LDH regulation? | Knock-in of mutant LDHA alleles in isogenic cell lines |
| Where is LDH localized in live cells? | Tagged knock-in of LDHA with fluorescent protein for imaging |
| Does LDH overexpression alter metabolic flux? | Overexpression of LDHA or LDHB in cell lines, followed by metabolomics |
| Which genes cooperate with LDH in cancer? | CRISPR library screening in LDH-dependent cancer cells |
How to Study the L-lactate dehydrogenase (NAD+) activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| NADH absorbance assay | LDH enzymatic activity via NADH production or consumption | Clinical serum LDH measurement; inhibitor screening |
| Kinetic analysis | Km, Vmax, inhibition constants | Characterizing LDH from different organisms or mutants |
| CRISPR knockout | Loss-of-function effects on metabolism and growth | Testing LDHA dependency in cancer cells |
| Point mutation | Role of specific residues in catalysis or regulation | Dissecting active-site and allosteric mechanisms |
| Knock-in tagging | Protein localization and interactions | Live-cell imaging of LDH isoforms |
| Overexpression | Gain-of-function effects on flux and signaling | Modeling LDH upregulation in cancer |
| Metabolomics | Lactate, pyruvate, NAD+/NADH levels | Assessing metabolic reprogramming |
| CRISPR library screening | Genes that modulate LDH dependency | Identifying combination targets in cancer |
Enzymatic activity assays
L-lactate dehydrogenase (NAD+) activity is routinely measured by monitoring the reduction of NAD+ to NADH at 340 nm or the reverse reaction. Total LDH activity in serum or cell lysates is a standard clinical and research assay. Kinetic parameters such as Km and Vmax can be determined using purified enzyme or lysates, and inhibition by compounds like galloflavin or oxaloacetate can be quantified.
Genetic and CRISPR-based perturbation
CRISPR knockout, point mutation, knock-in, and overexpression models allow researchers to dissect the specific contributions of LDH isoforms and catalytic residues. For example, knocking out LDHA in cancer cells reduces lactate production and can impair tumor growth. Point mutations in the active site can separate catalytic activity from protein-protein interactions, while tagged knock-ins enable localization studies.
Metabolic flux analysis and metabolomics
Measuring lactate and pyruvate levels, NAD+/NADH ratios, and isotopic labeling can reveal how LDH activity affects central carbon metabolism. The redox switch/redox coupling hypothesis can be tested by manipulating LDH expression and monitoring metabolic exchange. Such approaches are often combined with transcriptomics to assess downstream signaling, such as MYC target genes.
Structural and biophysical methods
X-ray crystallography, cryo-EM, and hydrogen-deuterium exchange mass spectrometry provide insights into LDH structure, allosteric regulation, and cofactor binding. These methods complement kinetic studies and can guide the design of isoform-specific inhibitors.
How CRISPR Can Be Used to Study GO:0004459 L-lactate dehydrogenase (NAD+) activity
Knockout
CRISPR knockout of LDHA or LDHB is used to eliminate specific L-lactate dehydrogenase (NAD+) activity and assess consequences on glycolysis, redox balance, and cell growth. For example, LDHA knockout in lymphoma cells can reduce lactate production and sensitize cells to metabolic stress. Knockout models are also valuable for validating inhibitor specificity.
Point Mutation
Point mutations in catalytic residues or allosteric sites of LDH can separate enzymatic activity from other functions. For instance, mutating the arginine that binds the lactate carboxylate can abolish catalysis while preserving structure, allowing researchers to test non-catalytic roles. Such models are essential for precise structure-function studies.
Knock-in
Knock-in of disease-associated or tagged LDH alleles enables physiological expression of mutant or fluorescently labeled enzymes. This approach can reveal how specific mutations affect LDH regulation, localization, and interaction partners in a native context. Knock-in models are also used to study isoform-specific functions.
Overexpression
Overexpression of LDHA or LDHB in cell lines mimics the elevated LDH activity seen in many cancers and hypoxic tissues. Such models help researchers study metabolic reprogramming, lactate signaling, and sensitivity to LDH inhibitors. Overexpression can be achieved via lentiviral transduction or CRISPR-mediated activation.
How EDITGENE Supports L-lactate dehydrogenase (NAD+) activity Research
Researchers studying L-lactate dehydrogenase (NAD+) activity-related genes often need to determine whether a candidate gene is causally involved in a metabolic or disease phenotype, and CRISPR-based models provide the most direct way to establish such causality. EDITGENE offers a comprehensive suite of services to generate and characterize these models.
Contact EDITGENE today to design your custom CRISPR model for L-lactate dehydrogenase (NAD+) activity research.
Frequently Asked Questions About L-lactate dehydrogenase (NAD+) activity
What is L-lactate dehydrogenase (NAD+) activity?
It is the enzyme activity defined by GO:0004459 that catalyzes the reversible conversion of (S)-lactate to pyruvate using NAD+ as a cofactor, producing NADH and H+.
What genes are involved in L-lactate dehydrogenase (NAD+) activity?
Key genes include LDHA, LDHB, and LDHC in humans, as well as bacterial ldh genes in organisms such as Alcaligenes eutrophus and Moorella thermoacetica.
What is the reaction catalyzed by L-lactate dehydrogenase?
The reaction is (S)-lactate + NAD+ = pyruvate + NADH + H+, as defined by the Gene Ontology.
How is L-lactate dehydrogenase activity measured?
It is commonly measured by monitoring NADH production or consumption at 340 nm in serum or cell lysates, a standard clinical assay.
Why is LDH activity important in cancer?
Many cancer cells rely on high LDH activity for anaerobic glycolysis; inhibiting LDH can suppress tumor growth and downregulate MYC in lymphoma cells.
What are the clinical uses of LDH measurements?
Serum LDH is used as a biomarker for tissue damage, hemolysis, and tumor burden, and total LDH activity is a routine clinical test.
Can LDH be inhibited by drugs?
Yes, compounds such as galloflavin inhibit LDH activity and have shown effects in lymphoma cells through NAD/NADH-dependent mechanisms.
What is the role of NAD+ in LDH activity?
NAD+ acts as the electron acceptor, being reduced to NADH during the conversion of lactate to pyruvate; the NAD+/NADH ratio influences reaction direction.
How is LDH activity regulated?
It is regulated by transcription (e.g., HIF1A), allosteric mechanisms, and the availability of substrates and cofactors; recent studies reveal allosteric regulation beyond tetramerization.
What model systems are used to study LDH?
CRISPR knockout, point mutation, knock-in, and overexpression cell models, as well as bacterial and thermophilic enzymes, are widely used.
Conclusion
L-lactate dehydrogenase (NAD+) activity (GO:0004459) is a central metabolic function that enables cells to balance redox state and adapt to anaerobic conditions. Its roles in cancer, tissue damage, and microbial metabolism make it a high-value target for both basic and translational research. By combining precise CRISPR models with biochemical and metabolomic assays, researchers can dissect the mechanisms and disease relevance of this enzyme activity.
References
- 1. Rosenbaum FP et al.. 2021. Lactate metabolism in strictly anaerobic microorganisms with a soluble NAD(+) -dependent l-lactate dehydrogenase.. Environ Microbiol 23(8):4661-4672 PMID: 34190373
- 2. Vanderlinde RE. 1985. Measurement of total lactate dehydrogenase activity.. Ann Clin Lab Sci 15(1):13-31 PMID: 3882046
- 3. Cai H et al.. 2025. Allosteric regulation of L-lactate dehydrogenase: Beyond effector-mediated tetramerization.. Protein Sci 34(7):e70206 PMID: 40563163
- 4. Steinbüchel A et al.. 1983. NAD-linked L(+)-lactate dehydrogenase from the strict aerobe alcaligenes eutrophus. 2. Kinetic properties and inhibition by oxaloacetate.. Eur J Biochem 130(2):329-34 PMID: 6825698
- 5. Furukawa S et al.. 1981. Inhibition of lactate dehydrogenase activity by polymeric NAD derivatives with different NAD densities.. Eur J Biochem 114(1):101-4 PMID: 7011800
- 6. Cerdán S et al.. 2006. The redox switch/redox coupling hypothesis.. Neurochem Int 48(6-7):523-30 PMID: 16530294
- 7. Vettraino M et al.. 2013. Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells through NAD/NADH-dependent inhibition of sirtuin-1.. Anticancer Drugs 24(8):862-70 PMID: 23797802
- 8. Rosenbaum FP et al.. 2025. Purification and characterization of a thermophilic NAD(+)-dependent lactate dehydrogenase from Moorella thermoacetica.. FEBS Open Bio 15(5):714-725 PMID: 39801223
